Cognitive Subscale News Today

A study indicated that crossword fans had better cognitive function in old age, but experts say it’s still a cryptic question

The open-label study evaluated the safety and tolerability, biological activity, blood biomarkers and preliminary efficacy of low-dose interleukin 2 (ld IL-2) in 8 patients with Alzheimer’s disease (AD). The academic study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital.The additional cl...

Last weeks FDA approval of the anti-amyloid lecanemab is being hailed by some Alzheimers experts as a major advance; others are less certain and have concerns about the drugs efficacy, safety, and cost.

The academic proof-of-concept open-label study evaluated the biological activity, cytokine and chemokine blood biomarkers, safety, and preliminary efficacy of low-dose interleukin-2 (ld IL-2) in 8 patients with mild-to-moderate AD. The study was conducted by Dr. Appel and Dr. Faridar at the Houston Methodist Hospital. Coya’s investigational low-dose interleukin-2 (ld IL-2) for subcutaneous administration has been designed to enhance in vivo the anti-inflammatory function of regulatory T ce...

FDA advisory committee determines phase 3 study of lecanemab, a monoclonal antibody directed against amyloid beta confirms the drugs clinical benefit for patients with Alzheimers disease.

Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist theres more to the story ― especially with the control agent used.

By targeting the precuneus in patients with Alzheimers disease, investigators using rTMS are hoping to stimulate or repair neural connections in the default mode network.

Sinaptica Therapeutics Announces Publication of Positive Results from Phase II Trial Evaluating the Potential of Precision-Delivered Noninvasive Neurostimulation Treatment for Mild-to-Moderate Alzheimer’s Disease - read this article along with other careers information, tips and advice on BioSpace

People with Alzheimer's may experience cognitive and neuropsychiatric symptoms at an early stage due to dysfunction of the locus coeruleus-noradrenergic system.

Noradrenergic drugs showed an overall small positive effect on global cognition and a larger positive effect on apathy in patients with Alzheimer disease.